ALCAM Regulates Motility, Invasiveness, and Adherens Junction Formation in Uveal Melanoma Cells by Jannie, Karry M. et al.
ALCAM Regulates Motility, Invasiveness, and Adherens
Junction Formation in Uveal Melanoma Cells
Karry M. Jannie, Christopher S. Stipp, Joshua A. Weiner*
Department of Biology, The University of Iowa, Iowa City, Iowa, United States of America
Abstract
ALCAM, a member of the immunoglobulin superfamily, has been implicated in numerous developmental events and has
been repeatedly identified as a marker for cancer metastasis. Previous studies addressing ALCAM’s role in cancer have,
however, yielded conflicting results. Depending on the tumor cell type, ALCAM expression has been reported to be both
positively and negatively correlated with cancer progression and metastasis in the literature. To better understand how
ALCAM might regulate cancer cell behavior, we utilized a panel of defined uveal melanoma cell lines with high or low
ALCAM levels, and directly tested the effects of manipulating these levels on cell motility, invasiveness, and adhesion using
multiple assays. ALCAM expression was stably silenced by shRNA knockdown in a high-ALCAM cell line (MUM-2B); the
resulting cells displayed reduced motility in gap-closure assays and a reduction in invasiveness as measured by a transwell
migration assay. Immunostaining revealed that the silenced cells were defective in the formation of adherens junctions, at
which ALCAM colocalizes with N-cadherin and ß-catenin in native cells. Additionally, we stably overexpressed ALCAM in a
low-ALCAM cell line (MUM-2C); intriguingly, these cells did not exhibit any increase in motility or invasiveness, indicating
that ALCAM is necessary but not sufficient to promote metastasis-associated cell behaviors. In these ALCAM-overexpressing
cells, however, recruitment of ß-catenin and N-cadherin to adherens junctions was enhanced. These data confirm a
previously suggested role for ALCAM in the regulation of adherens junctions, and also suggest a mechanism by which
ALCAM might differentially enhance or decrease invasiveness, depending on the type of cadherin adhesion complexes
present in tissues surrounding the primary tumor, and on the cadherin status of the tumor cells themselves.
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Introduction
The immunoglobulin superfamily (IgSF), a class of proteins with
765 putative members in humans [1] represents one of the most
ancient and diverse families of cell adhesion proteins. Not
surprisingly, IgSF members are key players in numerous
developmental and pathological processes [2–5]. Activated Leu-
kocyte Cell Adhesion Molecule (ALCAM; also reported as
CD166, DM-GRASP, neurolin, and BEN), an IgSF member,
has been implicated in the regulation of many developmental
events, including hematopoiesis [6–8], osteogenesis [9], T cell
activation [10–12], and neurite outgrowth, fasciculation, and
targeting [13–21]. Some of these studies suggested roles for
ALCAM based on its expression pattern alone, while others
utilized a variety of in vitro assays to identify ALCAM functions.
To assess in vivo roles, we generated the first null mutation of
ALCAM in any model organism by targeting the Alcam locus in
mice [22]. ALCAM-null mice are viable and fertile, suggesting
that ALCAM’s functions in vivo may not be as broad as assumed
from these earlier studies, although a high degree of functional
redundancy among IgSF members is also likely.
Nevertheless, we found that ALCAM-null mice do display
several nervous system defects predicted by previous studies,
including disrupted fasciculation of both motor and retinal
ganglion cell axons [22], and mistargeting of retinal ganglion cell
axons within the superior colliculus [23]. In addition, ALCAM-
null mice on a mixed C57BL/6-129 background exhibit retinal
dysplasias, including disrupted organization of the outer nuclear
layer photoreceptor neurons and invagination of the adjacent
retinal pigment epithelium (RPE) and choroid (choriocapillaris)
[22]; these dysplasias are greatly reduced on a congenic C57BL/6
background, however (data not shown). This last phenotype was
initially puzzling, since expression of ALCAM in the retina is
restricted to retinal ganglion cells and a subset of inner nuclear
layer amacrine cells, with no expression detectable in photorecep-
tor neurons or the RPE. We found, however, high levels of
ALCAM expression in melanocytes and stromal cells of the
choroid [22], a pigmented tissue that nourishes the RPE and
photoreceptor cells and provides much of the blood supply to the
eye (for review see ref. [24]). This previously undocumented
expression, as well as the fact that choroidal melanocytes were
found within ectopic retinal folds [22] suggests that in the absence
of ALCAM, the structure and/or function of melanocytes in the
uvea, which includes the choroid, iris, and ciliary body, might be
disrupted.
We found this phenotype to be particularly interesting in light of
dozens of reports identifying ALCAM as a potential regulator of
tumor cell behavior. Indeed, ALCAM has been implicated in the
progression and metastasis of cutaneous melanoma [25], prostate
carcinoma [26,27], breast cancer [28–30], colorectal carcinoma
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[33], among others (for review see ref. [5]). Although ALCAM has
been implicated in these numerous pathological states, it is as yet
unclear how ALCAM contributes to metastasis. Existing reports
are paradoxical, with ALCAM gene expression being highly
upregulated in some cancers [25,31,34] and greatly downregulat-
ed in others [28,35,36]. Unfortunately, these data are necessarily
correlative in nature; therefore, an understanding of the contri-
bution of ALCAM to cancer progression and, indeed, normal cell
motility and adhesion, has been hampered by a lack of studies
aimed at directly manipulating ALCAM levels within particular
cell lines and determining the outcome of this manipulation.
Here, we sought to address this by utilizing a number of defined
uveal melanoma cell lines with high or low ALCAM levels, and
testing the effects of manipulating these levels on cell motility,
invasiveness, and adhesion using multiple measures. Uveal
melanoma, the most common form of primary intraocular cancer,
is often derived from the choroid, is highly metastatic, and results
in death in 50% of patients [37]. Previous microarray analysis of
two uveal melanoma cell lines identified ALCAM as one of the
genes most upregulated in invasive cells (line MUM-2B) compared
to non-invasive cells (line MUM-2C) [38]. We find that, across
several uveal melanoma cell lines, ALCAM expression positively
correlates with cell motility. Silencing of ALCAM using targeted
shRNAs in MUM-2B results in both impaired cell motility and
reduced invasive capacity in an in vitro assay, consistent with an
observed reduction in matrix metalloproteinase activation. Con-
versely, forced expression of ALCAM in the normally ALCAM-
negative line MUM-2C did not increase cell motility or
invasiveness, demonstrating that ALCAM is necessary but not
sufficient for this cell behavior. Interestingly, we also find an effect
of ALCAM on cadherin-based adherens junctions. In MUM-2C
cells, forced expression of ALCAM results in increased recruitment
of neural (N)-cadherin and ß-catenin to cell-cell contacts.
Conversely, silencing of ALCAM expression in MUM-2B disrupts
the formation of adherens junctions. These data represent the first
description of ALCAM function in uveal melanoma cells, indicate
cooperation between ALCAM and cadherins in mediating cell
adhesion, and suggest that ALCAM’s ultimate effect on metastasis
might depend on the cadherin status of surrounding tissues in
conjunction with the cadherin status of the tumor cells.
Methods
Reagents, Cell Culture Media, Antibodies
DMEM, RPMI-1640, Anti-GFP (rabbit), trypsin-EDTA solu-
tion, HEPES, EHS laminin and all fluorescent-tagged secondary
antibodies were from Invitrogen (Carlsbad, CA, USA). Anti-N-
cadherin and anti- ß-catenin mouse monoclonal antibodies were
purchased from Becton Dickinson (Franklin Lakes, NJ, USA).
Anti-MMP-2 rabbit polyclonal antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Sodium
orthovanadate, anti-pan-cadherin, anti- ß-tubulin, and poly-L-
lysine (0.01%) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Anti-GFP (mouse) and protease inhibitor cocktail
EDTA-free mini tablets were from Roche (USA). Supersignal
West Pico reagents, BCA assay reagents, and HRP-conjugated
anti-mouse and anti-rabbit secondary antibodies were supplied by
Thermo Scientific (Rockford, IL, USA). HRP-conjugated anti-
goat secondary antibody was purchased from Jackson ImmunoR-
esearch (West Grove, PA, USA). Fetal Bovine Serum (FBS) was
purchased from Atlanta Biologicals (Lawrenceville, GA, USA).
Mouse monoclonal anti-ALCAM 3A6 antibody was purchased
from Millipore (Billerica, MA, USA). Goat anti-ALCAM AF656
was purchased from R&D Systems (Minneapolis, MN, USA).
Anti-ALCAM HB-2 antibody was the kind gift of Solomon Ofori-
Acquah (Emory University School of Medicine, GA, USA).
Puromycin and G418 were supplied by InvivoGen (San Diego,
CA, USA) and Research Products International Corp. (Mt.
Prospect, IL, USA), respectively.
Cell Culture Conditions
Cell lines were grown as follows: human uveal melanoma cell
lines OCM-1A, MUM-2B, MUM-2C, C918, M619, sh5, sh6,
sh5rxd, and 2C-ALC were maintained in RPMI-1640 supple-
mented with 10% FBS; selection was maintained in sh5 and sh6
with 1 mg/ml puromycin; in sh5rxd with 1 mg/ml puromycin and
250 mg/ml G418; in 2C-ALC with 250 mg/ml G418. HEK cells
and the retroviral packaging cell line GP2-293 was maintained in
DMEM supplemented with 10% FBS. All cell lines were
maintained at 37 degrees Celsius in 5% carbon dioxide. The
MUM-2B and MUM-2C lines were the kind gift of Dr. Elizabeth
Seftor (Children’s Memorial Research Center, Chicago, IL, USA);
the OCM-1A, C918, and M619 lines were the kind gift of Dr.
Karla Daniels (University of Iowa, Iowa City, IA, USA).
Immunohistochemistry
Cells were grown in 24-well dishes on glass coverslips coated
with poly-L-lysine (0.01%) and laminin (10 mg/ml). Cells were
grown on coverslips until at the desired confluency, then fixed for
15 minutes in 4% paraformaldehyde, rinsed with 16PBS, and
blocked in standard blocking solution (2.5% BSA, 0.1% Triton X-
100, 0.02% sodium azide) for 1 hour. Primary antibodies were
diluted in blocking solution and incubated on coverslips overnight
at 4 degrees Celsius. Coverslips were rinsed in 16PBS and
secondary antibody diluted in 16PBS was added for 1 hour at
room temperature. Coverslips were rinsed in 16PBS containing
DAPI (49,6-diamidino-2-phenylindole) to stain nuclei, then rinsed
once with water and set on filter paper to dry. After drying,
coverslips were mounted on glass slides using GelMount (Biomeda
Corporation, Foster City, CA, USA). ß-catenin-positive regions
between two cells were scored as strong, weak, or non-existent as
shown below in the text and figures. Contacting cells in a
minimum of three independent fields were scored.
Plasmids and Vectors
The sh5 and sh6 cell lines were created using viral transduction
of shRNA constructs in the pSIREN-RetroQ vector. Hairpin
sequences were cloned into the vector between 59 BamHI and 39
EcoRI sites.
The sequence of the sh5 insert is: 59-GAT CCG TAT GTC
TGC GAA ACT GCT CTG TTC AAG AGA CAG AGC AGT
TTC GCA GAC ATA TTT TTT CTA GAG-39.
The sequence of sh6 is: 59-GAT CCG TCA AGC AAC CAT
CTA AAC CTG TTC AAG AGA CAG GTT TAG ATG GTT
GCT TGA TTT TTT CTA GAG-39. The shRNA-containing
plasmids were cotransfected into GP2-293 cells along with pCMV-
VSV-G to produce virus particles.
The 2C-ALC cell line was created by viral transduction of
pWD201 into MUM-2C cells. The plasmid was previously
described in [39].
To create the sh5rxd cell line, sh5 cells were transduced a
second time with the construct pWD-ALCAM-GFP-mut3. This
plasmid was created by first cloning full-length ALCAM from
pWD201 into pEGFPN1 at SalI and AgeI sites to create
pEGFPN1-ALCAM. To avoid shRNA knockdown of the rescue
plasmid, three silent mutations were introduced into this plasmid
by use of the Stratagene QuikChange kit, using the following
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TG; Reverse – CTC CTG CAG AGC AGT CTC ACA AAC
AT. The resulting plasmid, pEGFPN1-ALCAM-mut3 was sub-
jected to PCR using primers containing BamHI and EcoRI ends
to yield a full-length ALCAM fragment tagged at the C-terminus
with GFP. This fragment was cloned into the pLXIN vector to
yield pLXIN-ALCAM-GFP-mut3.
pCMV-VSV-G, encoding a viral envelope protein was the kind
gift of Chris Stipp (University of Iowa, Iowa City, IA, USA).
The HEK-sh0 and HEK-sh2 cell lines were created by transient
transfection of HEK cells using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) with either a negative control (sh0) construct
in pGeneClip-hMGFP, or an shRNA against ALCAM (sh2) in
pGeneClip-hMGFP (SABiosciences, Valencia, CA, USA). The
sequence of the sh0 hairpin is: 59 – TCT CGG AAT CTC ATT
CGA TGC ATA CCT TCC TGT CAG TAT GCA TCG AAT
GAG ATT CCC T –39. The sequence of the sh2 hairpin is: 59 –
TCT CGT CAG GAT GCT GGA AAC TAT GTC TTC CTG
TCA ACA TAG TTT CCA GCA TCC TGA CT –39.
Retroviral Transduction
The stable cell lines sh5, sh6, 2C-ALC, and sh5rxd were created
by retroviral transduction. The appropriate constructs were
cotransfected, along with pCMV-VSV-G, into the GP2-293
packaging cell line. Conditioned media was harvested from the
GP2-293 cells, filtered, supplemented with 4 mg/ml polybrene,
and added to the appropriate parental cell line. The following day,
the media was removed from the parental cell line, and
conditioned media from the GP2-293 cells was added again. This
process was repeated a total of three times. After the final day of
incubation in conditioned media, the parental cells were grown for
24 hours in standard growth medium, and then appropriate
selection agents were added.
Gap Closure Assay/time-lapse Imaging
Confluent cultures were grown in 6 cm dishes. A 10 ml pipet tip
was used to inscribe a ‘‘wound gap’’ in the confluent layer of cells.
Cells were washed twice with 16PBS, then RPMI-1640 media
containing 10% FBS and 25 mM HEPES was added. The dishes
were covered and placed on a custom stage heater that maintained
media temperature at ,37 degrees Celsius. To analyze cell
motility, phase contrast time-lapse microscopy was done using a
QICAM camera (Q Imaging, Surrey, British Columbia, Canada)
and 106objective on a Leica DM-IRB microscope. Images were
collected every 10 minutes for 8 hours, or until cells closed the
wound gap. Analysis of cell migration was conducted by using
QImagePro (Q Imaging, Surrey, British Columbia, Canada). The
initial width of the gap was measured at three different places
along the length of the wound, and the time until the cells closed
the gap was recorded for each. The three speeds were calculated
and averaged together to yield a value for that trial. Each reported
speed represents at least three independent trials.
RNA, cDNA, and RT-PCR
RNA was extracted from 10 cm dishes of confluent cells using
Trizol
TM reagent (Invitrogen, Carlsbad, CA, USA). RNA was
subsequently reverse transcribed into cDNA using the ProtoScript
FirstStrand cDNA kit (NEB, Ipswich, MA, USA). cDNA was then
subjected to PCR (30–35 cycles) using primers that spanned an
intron of either ALCAM, MMP-2, or GAPDH.
Preparation of Cell Lysates
Cells were grown until confluent in 10 cm dishes, growth
media was aspirated, and cells were washed twice with 16PBS.
To a 10 cm dish, 1 ml of Mild Lysis Buffer (1% NP-40,
100 mM Tris-HCl pH7.4, 300 mM NaCl, 10 mM NaF,
0.5 mM sodium orthovanadate, 1 protease inhibitor cocktail
EDTA-free mini tablet per 10 ml) was added. Cells were
incubated for 10 minutes on ice, then scraped into an
eppendorf tube. The lysate was spun at 4 degrees Celsius in
a table top microcentrifuge for 10 minutes at 16,000 g to pellet
cell debris. The protein concentration of the resulting superna-
tant was quantified using a BCA assay.
Western Blots
For all western blots, 20 micrograms of total protein was loaded
per sample. For all western blots except MMP-2, lysates were run
on 9% acrylamide running gels with a 4% acrylamide stacking gel.
Lysates blotted for MMP-2 were run on precast 4–20% gradient
gels. Gels were run at 185 volts constant. Protein was then
transferred to 0.45 mm nitrocellulose using a ThermoFisher
electrotransfer apparatus at 0.4 amps constant. After transfer,
the nitrocellulose membrane was blocked for 1 hour at room
temperature in 5% dry milk in 0.05% Tween20-TBS (for rabbit
and mouse primary antibodies) or in 0.05% Tween20-TBS (for
goat primary antibodies). Primary antibodies were diluted in
blocking solution and incubated overnight at 4 degrees Celsius.
The blots were washed 3 times in 0.05% Tween20-TBS, and
secondary antibodies were diluted in 0.05% Tween20-TBS and
incubated with the blot for 1 hour at room temperature. The blots
were washed with 0.05% Tween20-TBS three times, then
developed using West Pico reagents (ThermoFisher Scientific,
Rockford, IL, USA).
Gelatinase Assay
Cells were grown to confluency in a 10 cm dish. Growth
medium was removed and replaced with 5 ml of serum-free
medium for 36 hours. The media were harvested, filtered
through a 0.45 micron filter to remove cells and debris, and
mixed 1:1 with non-reducing sample buffer. Samples were
treated as in [40], and 10 ml loaded onto an SDS-PAGE gel
that included 0.1% gelatin.
Invasion Assay
The CytoSelect
TM 24-well Invasion Assay, Basement Mem-
brane, Colorimetric format (Cell Biolabs, Inc., San Diego, CA,
USA) was used according to manufacturer’s protocol. Briefly,
300 ml of a 0.5610
6 cells per milliliter solution were plated in
serum-free RPMI-1640 in the upper chamber of an insert. The
bottom portion of the well was filled with 500 ml of RPMI-1640
containing 10% FBS and penicillin-streptomycin. Cells were
incubated for 8 hours at 37 degrees Celsius, 5% carbon dioxide.
After incubation, inserts containing invasive cells were removed
and stained with the provided cell stain solution. Stained cells in
three non-overlapping fields centered at the highest cell density
were counted at 106magnification on an inverted microscope.
Survival Assay
Cells were trypsinized, counted on a hemocytometer, and
120,000 cells were plated in triplicate in single wells of a 24-well
plate. The cells were incubated for 8 hours at 37 degrees Celsius
and 5% carbon dioxide, then trypsinized and counted on a
hemocytometer.
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To maintain a homogeneous population of ALCAM-expressing
or ALCAM-silenced cells, the sh5, 2C-ALC, and sh5rxd cell lines
were flow-sorted using a FACSDiva (Becton Dickinson, Franklin
Lakes, NJ, USA). Both sh5 and 2C-ALC were sorted using the
anti-ALCAM 3A6 antibody (Millipore, Billerica, MA, USA) and
phycoerythrin anti-mouse secondary antibody. For sh5, low-
ALCAM cells were kept and high ALCAM cells were discarded.
For 2C-ALC, ALCAM-positive cells were kept, and ALCAM-
negative cells were discarded. The sh5rxd cell line was sorted using
the cytoplasmic GFP tag on the full-length ALCAM construct they
were transduced with; GFP-positive cells were kept and GFP-
negative cells were discarded.
Results
ALCAM Expression Correlates with Cell Motility in Uveal
Melanoma Cell Lines
To begin to address the role of ALCAM in tumor cell behavior,
we assembled a panel of five uveal melanoma cell line stocks:
OCM-1A, MUM-2B, MUM-2C, C918, and M619. All cell lines
had been previously characterized by cell phenotype, invasive
potential, and vasculogenic mimicry [38–42]. Two of the lines,
OCM-1A and MUM-2C, are poorly invasive and resemble
normal uveal melanocytes, while the remaining three cell lines
were characterized as highly invasive, based on the ability to
invade a collagenous matrix-coated polycarbonate membrane.
MUM-2B and MUM-2C were initially reported to be isolated
from the same metastasis from a primary uveal melanoma, and
found to be phenotypically divergent: MUM-2B is epithelioid,
while MUM-2C is spindle-shaped [38]. Microarray analysis of
these two lines revealed that ALCAM was one of the most up-
regulated genes (8.3-fold) in highly invasive MUM-2B cells versus
poorly invasive MUM-2C cells [38]. Subsequent analysis of short
tandem repeats in the genomic DNA of these uveal melanoma
lines indicates that MUM-2B and MUM-2C are, in fact, unlikely
to have derived from the same metastasis [43]. Folberg and
colleagues (2008) additionally present evidence that OCM-1A and
MUM-2C share the same origin, as do MUM-2B, M619, and
C918; our data below are consistent with this. Therefore, while we
initially examined all five cell lines, most of our work has focused
on MUM-2B and MUM-2C as exemplars.
We first utilized a gap-closure assay as one measure of the
motility of each cell line. Freshly confluent monolayers were
inscribed with a gap using a micropipet tip, and movement of cells
back into the gap was monitored by time-lapse imaging. MUM-2B
cells moved more quickly to close the gap than did MUM-2C cells,
and had completely closed the gap by 8 hours (Fig. 1A). Time-
lapse analysis showed that MUM-2B cells appeared to move as a
cohesive sheet across the empty space of the gap (Fig. 1A).
Contrastingly, MUM-2C cells failed to completely close the gap by
8 hours, and, unlike MUM-2B, individual cells could be seen
breaking away from the cell front and moving across the gap space
individually (Fig. 1A). Gap closure analysis of the remaining cell
lines revealed that M619 and C918 were fast-moving like MUM-
2B, while OCM-1A was slow-moving like MUM-2C. The average
speed of each cell line was calculated from three independent gap
closure trials (Fig. 1B). MUM-2B, C918, and M619 all moved at
speeds 2–3 fold greater than OCM-1A and MUM-2C (Fig. 1B).
Next, we assayed ALCAM expression in the five cell lines by
both western blot (Fig. 1C) and RT-PCR (Fig. 1D). ALCAM
protein expression was undetectable in OCM-1A and MUM-2C;
in contrast, it was similarly high in MUM-2B, C918, and M619
(Fig. 1C). ALCAM can be shed from the membrane via the action
of ADAM-10 and ADAM-17 metalloproteinases [44,45]; therefore
we asked whether the lack of ALCAM protein in MUM-2C and
OCM-1A indicated a true lack of gene expression or simply
accelerated shedding and/or degradation. RT-PCR analysis of
cDNA demonstrated that few, if any, ALCAM transcripts are
present in these two cell lines, supporting the former possibility
(Fig. 1D). Finally, we analyzed the mode of migration of each cell
line, by plotting the cumulative percent of the initial gap closed
versus time: Three separate trials of the gap-closure assay in
MUM-2B (Fig. 1E) and MUM-2C (Fig. 1F) are shown. As noted
above, MUM-2B appeared to move as a cohesive sheet to close the
gap, and this linear mode of movement is reflected in the plots
(Fig. 1E). In contrast, MUM-2C did not seem to move as a
cohesive sheet, but instead, individual cells extended filopodia and
the cell front moved discontinuously to close the gap. This is
apparent in Figure 1F, where discrete ‘‘jumps’’ on the Y-axis
demonstrate this stop-and-start movement. Together, these data
demonstrate that ALCAM expression positively correlates with
cell motility in uveal melanoma cell lines.
Establishment of ALCAM-silenced MUM-2B Cell Lines by
shRNA Knockdown
To determine whether ALCAM regulates uveal melanoma cell
behavior, we began by knocking down ALCAM levels in MUM-
2B cells, which normally express high levels of ALCAM. This was
accomplished via transduction with retroviral constructs encoding
shRNAs targeted against the Alcam transcript. We tested a total of
6 different shRNA sequences, and focus here on two such
constructs, termed sh5 and sh6. Initial immunostaining of MUM-
2B cells infected with virus particles showed that many, though not
all, sh5-expressing cells completely lost detectable ALCAM, while
sh6 expression failed to silence ALCAM expression detectably
(data not shown). To isolate a purified population of silenced
MUM-2B cells, we performed FACS sorting using an antibody
against the ALCAM ectodomain, keeping only the population of
sh5-expressing cells that lacked detectable ALCAM. These cells,
termed sh5 cells, were utilized for experiments, using sh6-
expressing cells as well as parental MUM-2B cells as control
groups (Fig 2A, C–H).
To confirm that any phenotypes observed in sh5 cells were due
to ALCAM-silencing and not to off-target effects of the shRNA,
we established the sh5rxd ‘‘rescue’’ line. The sh5rxd cells were
transduced with retroviral constructs encoding both sh5 and a full-
length, C-terminally GFP-tagged human ALCAM construct
containing three silent point mutations, rendering it resistant to
sh5 knockdown. Expression of the GFP-tagged ALCAM was
validated by western blot using antibodies against either ALCAM
or GFP, which confirmed that sh5rxd expressed the higher
molecular weight GFP-tagged ALCAM but little, if any, endog-
enous ALCAM (Fig. 2B). As expected sh5rxd cells exhibited GFP-
and ALCAM-positive cell-cell junctions (Fig. 2I–K and data not
shown).
ALCAM-silenced Cells Display Reduced Motility and
Invasive Capacity
We first tested sh5 ALCAM-silenced cells in the gap closure
assay previously described, comparing them to both native
MUM-2B cells and sh6 control cells. Silencing ALCAM results
in a significant reduction in motility: sh5 cells exhibit a closure
rate nearly 50% lower than that of parental MUM-2B or non-
silenced sh6 cells (Fig. 3A). Although their velocity was markedly
reduced, the sh5 cells still appeared to move as a cohesive sheet,
and individual cells did not detach from the invasion front as in
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of a wound created with a pipet tip in a layer of confluent cells (A) reveals the difference in wound closure in MUM-2B vs. MUM-2C. The speed of 5
uveal melanoma cell lines (minimum 3 trials each) is quantified (B). Both OCM-1A and MUM-2C move at less than 0.5 microns per minute; MUM-2B,
C918, and M619 move at approximately 1.2 microns per minute. The speed of OCM-1A and MUM-2C are significantly different when compared to
MUM-2B (t-test; 1A vs. 2B, p=0.0008; 2C vs. 2B, p,0.0001). ALCAM protein expression as assayed by western blot shows that the cell lines fall into
two groups – those with detectable ALCAM, and those without detectable protein expression (C). Tubulin is shown as a loading control. RT-PCR
analysis of 4 of the 5 cell lines reveals that ALCAM mRNA expression mirrors protein expression (D). GAPDH is shown as a positive control. Percent
gap closure was tracked for MUM-2B (E) and MUM-2C (F), and revealed that these two representative cell lines differ in their modes of migration.
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silencing ALCAM impacts invasive capacity of MUM-2B uveal
melanoma cells. To accomplish this, we used a commercial
transwell assay (CytoSelect, Cell Biolabs, Inc.) comprising an
upper chamber separated from a lower chamber by a basement
membrane matrix-coated 8 mm (pore size) filter. A defined
number of cells were placed in the upper chamber and the
cultures incubated for 8 hours, following which the number of
cells that had invaded the matrix and reached the underside of
the filter was counted. As expected, the sh6 and sh5rxd cell lines
did not exhibit any statistically significant difference in invasive
capacity compared to MUM-2B (Fig. 3B). In contrast, ALCAM-
silenced sh5 cells showed a 50% reduction in invasive capacity,
consistent with the similar magnitude reduction in motility
observed in the gap closure assay (Fig. 3B).
While the tracking of the wound front is fairly linear in MUM-2B, the cell front of MUM-2C advances in a stop-and-start manner, due to loosely
associated single cells progressing into the gap. Error bars are mean 6 S.E.M.
doi:10.1371/journal.pone.0039330.g001
Figure 2. ALCAM expression is silenced in MUM-2B cells via shRNA, and rescued by re-expression of ALCAM-GFP. Western blots of
MUM-2B, ALCAM-silenced sh5, control sh6, and negative control MUM-2C reveal that ALCAM protein expression is nearly completely silenced in sh5,
but not in sh6 (A). Tubulin is shown as a loading control. ALCAM expression in the rescue cell line (sh5rxd, containing an ALCAM-GFP construct with
point mutations to evade knockdown) is similar to MUM-2B, as shown by western blot using an anti-ALCAM antibody (B; note that the GFP tag adds
,27 kDa to the size of the protein; reprobing the blot with anti-GFP antibody detects only the rescue band, as expected). Panel (C) shows DAPI-
stained nuclei of the sh5 cell line; immunostaining of sh5 confirms nearly complete knockdown of ALCAM protein expression (D, E). Panel (F) shows
DAPI-stained sh6 nuclei; ALCAM expression in this cell line is robust, and localized to points of cell contact (G, H). Panel (I) shows DAPI-stained nuclei
of the sh5rxd rescue cell line; ALCAM expression and localization in the rescue cells (J, K) is comparable to the sh6 cell line. Scale bar in (K) is 25
microns.
doi:10.1371/journal.pone.0039330.g002
ALCAM in Melanoma Motility and Adhesion
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39330Because the invasion assays were performed over a period of 8
hours, it was formally possible that sh5 cells simply proliferated
more slowly than MUM-2B, which might contribute to the
difference in the number of cells counted on the underside of the
transwell filter. To ascertain that this was not the case, we
performed a cell survival assay by plating a known number of cells
in standard tissue culture wells, incubating for 8 hours, and then
counting the cells. No significant differences were found in the
survival of MUM-2B, sh5, and sh6 cell lines after 8 hours (Fig. 3C)
or in growth at 24 hours (data not shown). Thus, our experiments
demonstrate that ALCAM expression is necessary for cell motility
and invasiveness in MUM-2B uveal melanoma cells.
ALCAM Overexpression is not Sufficient to Enhance
Migration and Invasive Capacity in MUM-2C Cells
If ALCAM expression is necessary for motility and invasiveness
in the MUM-2B uveal melanoma cell line, is ALCAM expression
sufficient to increase motility and confer invasiveness in the
normally ALCAM-negative MUM-2C line? To test this, we
created a stable cell line, termed 2C-ALC, by transducing MUM-
2C with a virus encoding full-length ALCAM. Expression of the
full-length ALCAM construct was confirmed by both western blot
(Fig. 4C) and immunohistochemistry (Fig. 4A, B). Expression level
of ALCAM in 2C-ALC was roughly comparable to that of MUM-
2B. As expected, ALCAM localized to cell-cell contacts in 2C-
ALC cells (Fig. 4B). Overexpression of ALCAM in the 2C-ALC
cell line, however, failed to enhance the velocity of cells in the gap
closure assay (Fig. 4D). 2C-ALC cells still often moved as
individual cells (similar to native 2C cells; Fig. 1F), and not as a
cohesive sheet like MUM-2B cells (data not shown). Overexpres-
sion of ALCAM was also not sufficient to enhance the invasive
capacity of 2C-ALC cells (Fig. 4E), nor did it affect the survival or
proliferation of the cell line (Fig. 4F).
ALCAM-silenced Cells Exhibit Reduced MMP-2
One likely way in which ALCAM could promote an invasive
phenotype is through regulation of matrix metalloproteinases
(MMPs). MMPs are zinc-dependent proteinases whose expression
has been implicated in processes such as tissue remodeling and
cancer metastasis. MMP-2, a 72 kDa protein also called gelatinase
A, is the most abundant of the MMPs and is documented as a
marker of poor prognosis in a variety of cancers [46–48].
Activation of MMP-2, and the additional gelatinase family protein
MMP-9, allows degradation of type IV collagen basement
membranes. MMPs are synthesized as pro-enzymes that must be
processed to their active form by proteolytic cleavage. Pro-MMP-2
is recruited from the extracellular milieu and processed by a
complex consisting of Type I MMP (MT1-MMP/MMP-14) and
tissue inhibitor of metalloproteinase-2 (TIMP-2); this process is
known to require full-length ALCAM [40]. Thus, we assayed
MMP-2 levels in our panel of melanoma cell lines via gelatin
zymography and western blot, where pro-MMP-2 appears as a
72 kDa band, and active MMP-2 appears as a ,64 kDa band.
In gelatin zymography, active MMP-2 appears as a clear,
Coomassie-negative band of ,64 kDa upon staining of the gel; the
‘‘pro-MMP2’’ band of 72 kDa is also active in this assay, in the
presence of SDS [40]. Because the pro-MMP2 band was much
more prominent in our conditioned media samples, we quantified
this band as a measure of MMP2 levels secreted by cells; in many
gels, we could see a faint ,64 kDa active band as well, which
tracked levels of the clearer pro-MMP2 band (data not shown).
Gelatin-clearing MMP-2 activity was strong in MUM-2B (Fig. 5A),
C918, and M619 cells (data not shown), all of which highly express
ALCAM (Fig. 1C), but not in the ALCAM-negative OCM-1A
Figure 3. ALCAM-silenced cells display reduced wound-gap
closure speed, invasive capacity, and MMP-2 activation. Closure
rate of cells in a wound-gap assay was determined for each cell line
listed (minimum of 3 trials each; A). The speed of sh5 cells was
significantly reduced compared to MUM-2B, sh6 control, and sh5rxd
rescue cells (ANOVA; p,0.05). Invasive capacity of each cell line was
assayed via transwell migration. The number of invasive cells was
standardized relative to MUM-2B for each cell line shown (minimum of
3 trials each; B). The average number of invasive MUM-2B cells per three
non-overlapping 106 fields was 806. The sh5 cell line displayed
significantly reduced invasive capacity compared to MUM-2B and
sh5rxd rescue (ANOVA; p,0.01). To ensure that differences in
invasiveness were not due to differences in growth or survival after
plating, an equivalent number of cells was plated for each line. Eight
hours later, the number of cells was assayed, and found to be
comparable between lines (C). Error bars are mean 6 S.E.M.
doi:10.1371/journal.pone.0039330.g003
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39330Figure 4. Expression of ALCAM in MUM-2C cells does not enhance wound-gap closure speed or invasive capacity. Immunostaining of
MUM-2C cells (A) reveals that ALCAM expression is virtually undetectable in these cells. DAPI-stained nuclei are shown in blue; ALCAM staining is
shown in red. In the 2C-ALC cell line (B), engineered to stably overexpress ALCAM, DAPI-stained nuclei are shown in blue, and ALCAM staining is
shown in red. ALCAM localizes to points of contact between cells in the 2C-ALC cell line. The expression of ALCAM in 2C-ALC is confirmed by western
blot in panel (C), and is undetectable in MUM-2C. Tubulin is shown as a loading control. The expression of ALCAM in 2C-ALC did not alter closure rate
in a wound-gap assay (D), nor did it enhance invasive capacity of 2C-ALC cells when compared with MUM-2C in a transwell migration assay (t-test;
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39330(data not shown) or MUM-2C (Fig. 5A). Next, we quantified
MMP-2 activity in the stable cell lines, sh5, sh6, and 2C-ALC
(Fig. 5A, B). We found that MMP-2 activation was reduced in sh5
by nearly 80% compared to parental MUM-2B, control sh6 cells,
and sh5rxd rescued cells (Fig. 5B). As expected from our previous
results with the 2C-ALC cell line (Fig. 4) MMP-2 activity was not
increased in 2C-ALC compared to parental MUM-2C (Fig. 5A,
B); again, this suggests that ALCAM is necessary, but not
sufficient, for an invasive cell phenotype in uveal melanoma.
Pro-MMP-2 was detectable in MUM-2B, sh5, sh6, and sh5rxd cell
lysates by western blot, indicating that even sh5 expressed this
enzyme (Fig. 5C). Consistent with the decreased invasive capacity
in sh5, the active form of MMP-2 was just barely detectable in sh5,
yet was clearly present in MUM-2B, sh6, and sh5rxd (Fig. 5C). It is
possible that sh5 ALCAM-silenced cells exhibit defects in both
MMP2 secretion and MMP2 activation, based on our combined
results.
Cadherin-based Junctions are Disorganized in ALCAM-
silenced Cells
Another way in which ALCAM could influence tumor cell
behavior is through the regulation of other adhesion molecules,
particularly those that have been implicated in metastasis, such as
classical cadherins (for reviews, see refs. [49–51]). Several previous
lines of evidence support such a hypothesis. First, a report by
Tomita and colleagues [52] described the coordinate recruitment
of epithelial (E)-cadherin and ALCAM to cell contacts upon
transfection of alpha-catenin into prostate cancer cell lines that
have lost this protein. Second, ALCAM has been shown to
colocalize with both alpha-catenin and filamentous actin in MV3-
Tiam1 cells [53]. Finally, ALCAM could be co-immunoprecipi-
tated with VE-cadherin and N-cadherin in PVMEC cells [54], and
has been reported to be present in the same lipid microdomain
compartments as cadherins [55].
We began by assessing the expression of cadherins in uveal
melanoma cell lines. Both MUM-2B (Fig. 6G) and MUM-2C
(Fig. 7E) expressed N-cadherin as well as ß-catenin; neither had
detectable levels of E-cadherin (data not shown). To determine
whether ALCAM silencing affects adherens junctions, we com-
pared N-cadherin and ß-catenin staining in sh5 (ALCAM-
silenced), sh6 (control), and sh5rxd (ALCAM-silenced+rescued)
cells. In parental MUM-2B cells (data not shown) or in sh6 control
cells, strong ß-catenin (Fig. 6B) and N-cadherin (Fig. 6E) staining
was localized to cell-cell contacts that were also ALCAM-positive,
and cells had a flattened, epithelioid shape. In contrast, sh5
silenced cells had disorganized ß-catenin (Fig. 6A) and N-cadherin
(Fig. 6D) junctions, a more spindle-like shape, and often grew on
top of each other. This phenotype was significantly rescued by re-
expression of ALCAM in the sh5rxd cell line (Fig. 6C, F).
Quantification (examples of ‘‘strong’’ and ‘‘weak’’ junctions are
shown in Fig. 6H) showed that the percentage of cells with
contiguous, strong ß-catenin-positive adherens junctions was
reduced from nearly 75% in control lines to ,25% in sh5
(Fig. 6H). Neither silencing of ALCAM in sh5 nor its re-expression
in sh5rxd appeared to affect levels of ß-catenin or N-cadherin
expression (Fig. 6G).
This phenomenon was not restricted to uveal melanoma cells.
Transient transfection of HEK293 cells with an shRNA construct
(sh2) confirmed to silence ALCAM also resulted in reduced ß-
catenin localization to cell-cell contacts, and a lack of strong
junctions (Fig. S1). In HEK293 cells transfected with a negative
control, scrambled shRNA (sh0), ß-catenin localization to cell
junctions was not perturbed (Fig. S1).
ALCAM Expression Enhances Cadherin-mediated Cell-cell
Contacts in the 2C-ALC Cell Line
Finally, we addressed whether ALCAM expression would be
sufficient to enhance the formation of cadherin-based adherens
junctions in 2C-ALC cells. Parental MUM-2C cells exhibited
weak, diffuse ß-catenin and N-cadherin staining, with few clear
cell-cell junctions (Fig. 7A, C). Expression of ALCAM in the 2C-
ALC cell line led to an increase in ß-catenin and N-cadherin
staining along the length of cell junctions, which colocalized
precisely with ALCAM (Fig. 7B, D). Despite this, cell morphology
remained fairly similar to MUM-2C’s spindle shape, and no
increase in total N-cadherin or ß-catenin levels was observed
(Fig. 7E). In parental MUM-2C cells, only ,15% of cells had ß-
catenin-positive junctions; in contrast, over 75% of 2C-ALC cells
did (Fig. 7F). Together with our analysis of sh5 silenced cells, these
data suggest that ALCAM expression is both necessary and
sufficient to promote the recruitment of N-cadherin and ß-catenin
to form adherens junctions in uveal melanoma cells.
Discussion
ALCAM has demonstrated functions in many critical devel-
opmental processes such as hematopoiesis [6–8], neurite
outgrowth [13–21], retinal ganglion cell targeting [23], and T-
cell activation [10–12]. ALCAM has also been implicated in
pathological states, such as cancer metastasis, but its role remains
somewhat confusing. ALCAM has been identified as a marker of
metastasis in many tumor cell types, and yet in other cases it has
been associated with inhibition of metastasis. Reports from the
literature thus present a paradox regarding ALCAM’s relation-
ship to tumor cell motility and invasiveness.
For example, initial studies described a positive correlation
between ALCAM expression and metastatic capacity or progres-
sion of cutaneous melanoma [25,32]. The role of ALCAM in
cutaneous melanoma was first addressed directly by the laboratory
of Guido Swart [56]. An amino terminal-truncated (dominant
negative) form of ALCAM was transfected into cutaneous
melanoma cells, and was found to diminish cell clustering and
enhance both motility in vitro and the transition from primary
tumor to tissue invasion in vivo. It appeared that the disruption of
homophilic ALCAM contacts thus resulted in increased metastatic
potential in cutaneous melanoma cell lines [56]; this was, however,
in contrast to previous expression data that predicted ALCAM
would promote invasion and metastasis.
When other cancer types are considered, the picture becomes
murkier – one study by Kristiansen and colleagues [35] found that
ALCAM protein expression is high in low-grade prostate cancer,
and is lost in higher-grade tumors. A study of colorectal cancer
demonstrated overexpression of ALCAM neoplastic regions
compared to normal surrounding tissue; membranous ALCAM
staining correlated with reduced patient survival [31]. Studies of
breast carcinoma also provide seemingly conflicting results: one
study [28] found that low ALCAM expression correlated with high
tumor grade and metastasis, while another [29] showed that
ALCAM is associated with smaller tumor diameter and grade.
p.0.05; the average number of invasive MUM-2C cells per three 106fields was 16; E). Growth and survival of MUM-2C and 2C-ALC is similar, as
assayed and described in Fig. 3 (F).
doi:10.1371/journal.pone.0039330.g004
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most common form of primary intraocular cancer, are lacking.
Our aim in initiating this study was to determine the role that
ALCAM plays in modulating invasiveness and motility in uveal
melanoma, and to provide mechanistic data that will contribute to
an understanding of why ALCAM up- and down-regulation might
be associated with different stages of different cancers. We describe
a correlation between ALCAM expression and motility in a gap
closure assay in uveal melanoma cells. These data suggested that
ALCAM plays a role in promoting motility and migration. We
further find that silencing of ALCAM in the invasive MUM-2B
line results in decreased motility, invasiveness, and MMP-2
activation.
Figure 5. ALCAM-silenced cells display reduced MMP-2 activity. Levels of pro-MMP-2 were assayed in media conditioned by each cell line by
gelatin zymography (A). Clear bands indicating pro-MMP-2 activity (which is activated by SDS; a faint ‘‘active’’ cleaved MMP2 band was present in
some gels but often too weak for robust quantification) are present in MUM-2B, sh6, and the sh5rxd cell lines, but are reduced in the ALCAM-silenced
sh5 cell line. MUM-2C and 2C-ALC display pro-MMP-2 levels that are lower than MUM-2B, and comparable to sh5 cells; the overexpression of ALCAM
in 2C-ALC fails to increase pro-MMP-2 activity beyond that of MUM-2C. A minimum of three independent gelatin zymography trials (except 2C-ALC, 2
trials) are quantified in (B). (C) Western blots of cell lysates shows that the activation of pro-MMP-2 in the sh5 cell line is reduced (higher molecular
weight band is pro-MMP-2; lower molecular weight band is active MMP-2) compared to MUM-2B, sh6, and the sh5rxd rescue cell line.
doi:10.1371/journal.pone.0039330.g005
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39330Our results have implicated ALCAM as a regulator of cadherin-
based adherens junctions in uveal melanoma cells. The disruption
of N-cadherin/ß-catenin-positive junctions we observe in AL-
CAM-silenced sh5 cells is striking. Typically, N-cadherin and ß-
catenin localize strongly to cell-cell contacts, colocalizing with
ALCAM. In ALCAM-silenced cells, however, both N-cadherin
and ß-catenin localization at cell contacts is markedly reduced – it
appears as if adherens junctions ‘‘fall apart’’ in the absence of
ALCAM. This is consistent with earlier findings by Ofori-Acquah
and colleagues [54], in which ALCAM co-immunoprecipitated in
multiple adherens junction complexes. We were not, however,
able to co-immunoprecipitate ALCAM with N-cadherin in uveal
melanoma cells, suggesting that any interaction may not be direct
or may be sensitive to our lysis conditions.
The cadherins have long been implicated in invasion and
metastasis, with N-cadherin/E-cadherin expression often dictating
invasive potential in cancer cells. In addition to mediating
intercellular and cell-matrix adhesive interactions, cell adhesion
molecules also modulate signaling pathways. Thus, changes in the
expression and localization of cell adhesion molecules can
influence tumor progression by both modulating the adhesion
status of a cell and by altering cell signaling. In many human
cancer types, including melanoma, the loss of E-cadherin function
is concomitant with expression of mesenchymal cadherins,
including N-cadherin [57,58].
N-cadherin has been shown to promote cell motility and
migration – in stark contrast to the anti-migratory properties of
E-cadherin [59,60]. N-cadherin is capable of overcoming E-
cadherin-mediated cell adhesion, resulting in induction of an
invasive phenotype [59,61]. This so-called ‘cadherin switch’ not
only occurs during the transition of cancer cells to an invasive
phenotype, but is also a hallmark of the epithelial-to-mesenchy-
mal transition that occurs during embryonic development. Given
that ALCAM expression can modulate N-cadherin localization at
cell-cell junctions, we can envision the following possibilities as to
how ALCAM status might influence the migratory and invasive
properties of uveal melanoma cell lines.
ALCAM-induced N-cadherin junction formation might en-
hance the ability of tumor cells to move into different surround-
ings. Stromal cells, fibroblasts, and blood vessel endothelial cells
express N-cadherin [62]. Positive regulation of N-cadherin
junctions by ALCAM could allow cancerous cells to successfully
move through adjacent N-cadherin-positive tissues by promoting
interactions with these cells, thereby enhancing the probability of
metastasis. This is an attractive hypothesis, given that the choroid
of the eye is rich in blood vessels, and that endothelial cells express
N-cadherin and vascular endothelial (VE)-cadherin [62]. When
accompanied by a loss of E-cadherin, the tumor cells may lose
their ability to interact with adjacent epithelial cell types.
Therefore, expression of ALCAM could promote a state of
dynamic adhesion, whereby cells dissociate from their primary site
and subsequently interact with adjacent stromal cells and
endothelial cells. In cases where adjacent cells are devoid of N-
cadherin expression, we speculate that ALCAM expression might
not serve to promote metastasis, as it would not increase the
interaction between the two cell types. Since our cells were devoid
of detectable E-cadherin expression, we were not able to observe
whether ALCAM has a similar effect on this or other cadherin
family members, though the literature suggests it does [52,54].
In addition to modulating adhesion specificity, ALCAM-
induced N-cadherin junction formation might also provide cells
with a pro-migratory signal. N-cadherin is capable of inducing
motility and invasion independent of E-cadherin status [61].
Breast cancer cells transfected with N-cadherin show increased
metastatic potential when injected into nude mice [59]. What N-
cadherin signaling pathway might lead to increased motility and
invasion? Fibroblast growth factor receptors (FGFRs) have been
shown to physically interact with N-cadherin, likely through
interactions between the fourth extracellular domain of N-
cadherin and the first two Ig-like domains of FGFRs [63,64]. It
is hypothesized that N-cadherin interaction with FGFRs facilitates
binding of fibroblast growth factor-2 (FGF2) to its receptor but
helps prevent internalization of FGFR. This, in turn, leads to
increased expression of FGFRs at the cell surface, which
contributes to sustained MAPK signaling. The end result is
increased motility, invasiveness, and secretion of matrix metallo-
proteinases, including MMP-9 [64].
The cutaneous-derived BLM cell line, being devoid of cadherin
expression, might not be subject to the same changes in signaling
induced by decreasing ALCAM-ALCAM interactions as would
our uveal melanoma cell lines. The reduction of homophilic
ALCAM interactions in a cell line lacking cadherins might free the
cells from interacting with each other, allowing migration of
individual cells into surrounding tissue. The reduction in
invasiveness we observe appears at odds with the finding that
amino-truncated ALCAM expression served to disrupt ALCAM
junctions and to reduce MMP-2 activation, but actually increased
the invasive capacity of BLM cutaneous melanoma cells [56] [40].
An attractive hypothesis that could account for the increased
invasiveness caused by a dominant-negative ALCAM [56] versus
our own results in which silencing ALCAM results in decreased
invasiveness, centers around the cadherin status of the cell lines
used in each study. BLM cells are devoid of N-, E-, and P-cadherin
expression [65], while both cell lines used in our study strongly
express N-cadherin (but not E-cadherin; P-cadherin was not
assayed).
Overall, our work confirms a previously suggested link between
ALCAM and cadherins [52,54], and provides a new example of
the regulation of cadherins by IgSF members. Nectins are IgSF
molecules that localize to adherens junctions in epithelial cells
[66,67], and influence E-cadherin-mediated adhesion [68,69]
appears to increase the overall strength of adhesion between cells.
All nectins associate with an intracellular binding partner, afadin,
which directly links nectins to the actin cytoskeleton [70]. Afadin
also associates with alpha-catenin [71,72]. As ALCAM’s intracel-
lular interaction partners are completely unknown, a key
component of our work going forward will be focused on
identifying such partners, and the signaling pathways associated
with them. It will also be important to determine the specificity of
the interaction between ALCAM and cadherins: can silencing of
Figure 6. Silencing of ALCAM disrupts N-cadherin and ß-catenin junctions. (A-F) Immunostaining of sh5 (A, D), sh6 (B,E), and sh5rxd (C,F)
cells for nuclei (DAPI; blue), ß-catenin or N-Cadherin (green), and ALCAM (red) reveal that adherens junctions are disorganized when ALCAM is absent
(A, D). Control sh6 cells and sh5rxd rescue cells, in contrast, have strong localization of ß-catenin and N-Cadherin at cell-cell contacts (B,E; C, F), where
ALCAM colocalizes. Overall levels of adhesion molecules were assayed in MUM-2B, sh5, sh5rxd, and sh6 by western blot (G). The levels of expression
detected by pan-cadherin, N-cadherin, and ß-catenin antibodies were similar across all cell lines. The proportion of cells that exhibited strong ß-
catenin-labeled cell-cell junctions was quantified and is shown in (H), as are representative examples of cell-cell junctions classified as strong or weak.
The number of sh5 cells forming strong ß-catenin junctions is significantly reduced in sh5 compared to sh5rxd (t-test, p,0.0001). Error bars are mean
6 S.E.M. Scale bars are 10 microns.
doi:10.1371/journal.pone.0039330.g006
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PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e39330Figure 7. ALCAM expression in 2C-ALC cells enhances formation of N-cadherin and ß-catenin junctions. (A, C) Immunostaining of 2C
cells for nuclei (DAPI; blue), ß-catenin or N-Cadherin (green), and ALCAM (red) reveal that ß-catenin is diffusely localized and not prominent at cell-cell
contacts. In contrast, 2C-ALC cells (B,D) display enhanced localization of ß-catenin and N-Cadherin to cell-cell contacts in the presence of ALCAM
expression. In the merged images, ALCAM colocalizes at adherens junctions and at points of contact between adjacent cells. Levels of adhesion
molecules were assayed in MUM-2C and 2C-ALC by western blot (E). The levels of pan-cadherin, N-cadherin, and ß-catenin are similar in both cell
lines. The proportion of cells forming strong ß-catenin positive junctions is shown in F. 2C-ALC cells have significantly more ß-catenin positive cell
junctions than do MUM-2C cells (t-test; p,0.05). Error bars are mean 6 S.E.M. Scale bars are 10 microns.
doi:10.1371/journal.pone.0039330.g007
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PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e39330ALCAM remove a variety of classical cadherins from adherens
junctions in different cell types? Several reports have demonstrated
that ALCAM and cadherins are present in the same lipid
microdomains [5,54,55]: does ALCAM regulate cadherin recruit-
ment to these rafts? New studies focused on identification of both
extracellular and intracellular binding partners of ALCAM will be
critical to understanding of the mechanisms by which ALCAM
regulates adherens junctions, cell motility, and invasive capacity.
Supporting Information
Figure S1 Silencing of ALCAM in HEK cells results in
disrupted ß-catenin junctions. HEK cells were transiently
transfected with an shRNA construct confirmed to silence
ALCAM (sh2), or a negative control scrambled shRNA (sh0).
Both constructs included a GFP marker to track transfected cells
(pseudocolored blue). HEK cells with silenced ALCAM expression
show reduced ß-catenin localization (green) to cell-cell contacts, as
well as reduced ALCAM expression (red; asterisk indicates an
untransfected cell with a higher expression level of ALCAM).
HEK cells transfected with the negative control shRNA, however,
display robust ALCAM expression that localizes to cell junctions,
and ß-catenin localizes strongly to cell junctions in these cells.
(DOC)
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